William Townsend

3.1k total citations · 1 hit paper
68 papers, 1.8k citations indexed

About

William Townsend is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, William Townsend has authored 68 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pathology and Forensic Medicine, 35 papers in Oncology and 25 papers in Genetics. Recurrent topics in William Townsend's work include Lymphoma Diagnosis and Treatment (40 papers), Chronic Lymphocytic Leukemia Research (23 papers) and CAR-T cell therapy research (21 papers). William Townsend is often cited by papers focused on Lymphoma Diagnosis and Treatment (40 papers), Chronic Lymphocytic Leukemia Research (23 papers) and CAR-T cell therapy research (21 papers). William Townsend collaborates with scholars based in United Kingdom, United States and Germany. William Townsend's co-authors include Lorenz E. Zimmerman, Ramon L. Font, David C. Linch, Elizabeth H. Phillips, Robert Marcus, Michael Herold, Wolfgang Hiddemann, Tom Moore, John F. Seymour and Rudolf Schlag and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

William Townsend

65 papers receiving 1.7k citations

Hit Papers

Obinutuzumab for the First-Line Treatment of Follicular L... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
    2017 461 citations Robert Marcus, Andrew Davies et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Townsend United Kingdom 22 897 877 375 371 365 68 1.8k
Raymond E. Felgar United States 22 891 1.0× 486 0.6× 1.4k 3.6× 682 1.8× 536 1.5× 38 2.8k
Marianne Tinguely Switzerland 25 793 0.9× 747 0.9× 482 1.3× 59 0.2× 281 0.8× 74 1.9k
Françoise Rigal‐Huguet France 25 1.0k 1.1× 869 1.0× 283 0.8× 78 0.2× 837 2.3× 66 2.7k
Alessandro Gozzetti Italy 28 619 0.7× 1.0k 1.2× 512 1.4× 110 0.3× 928 2.5× 147 2.8k
E. Hessey United Kingdom 6 448 0.5× 183 0.2× 732 2.0× 615 1.7× 710 1.9× 8 2.4k
Monica Monti Italy 32 481 0.5× 398 0.5× 224 0.6× 118 0.3× 722 2.0× 78 3.4k
Cyrille Touzeau France 29 586 0.7× 1.5k 1.7× 320 0.9× 333 0.9× 613 1.7× 204 3.0k
José C. Villasboas United States 18 389 0.4× 722 0.8× 488 1.3× 40 0.1× 105 0.3× 127 1.3k
Meyer R. Heyman United States 14 1.4k 1.6× 1.1k 1.3× 699 1.9× 752 2.0× 924 2.5× 22 2.8k
J P Sloane United Kingdom 22 730 0.8× 706 0.8× 388 1.0× 336 0.9× 250 0.7× 34 1.9k

Countries citing papers authored by William Townsend

Since Specialization
Citations

This map shows the geographic impact of William Townsend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Townsend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Townsend more than expected).

Fields of papers citing papers by William Townsend

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Townsend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Townsend. The network helps show where William Townsend may publish in the future.

Co-authorship network of co-authors of William Townsend

This figure shows the co-authorship network connecting the top 25 collaborators of William Townsend. A scholar is included among the top collaborators of William Townsend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Townsend. William Townsend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Topp, Max S., Monica Tani, Michael Dickinson, et al.. (2025). 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY. Hematological Oncology. 43(S3). 1 indexed citations
2.
Renders, Simon, Hervé Finel, William Townsend, et al.. (2024). Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study. Blood Advances. 8(21). 5571–5578.
3.
Tute, Ruth de, Nicholas Counsell, Laura Clifton‐Hadley, et al.. (2024). Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia. Leukemia. 38(4). 822–828.
4.
Townsend, William, et al.. (2023). Psychosis secondary to thyrotoxicosis that persisted post-thyroidectomy: a case report. BMC Psychiatry. 23(1). 750–750. 2 indexed citations
5.
Townsend, William, Wolfgang Hiddemann, Christian Buske, et al.. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 7(7). e919–e919. 27 indexed citations
6.
Townsend, William, Max S. Topp, Michael Dickinson, et al.. (2023). Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study. Hematological Oncology. 41(S2). 595–597. 1 indexed citations
7.
Roddie, Claire, Lorna Neill, Wendy Osborne, et al.. (2023). Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Advances. 7(12). 2872–2883. 64 indexed citations
8.
Halford, Sarah, Harriet S. Walter, Pam McKay, et al.. (2021). Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).. Journal of Clinical Oncology. 39(15_suppl). 3115–3115. 26 indexed citations
9.
Hess, Brian, William Townsend, Weiyun Z. Ai, et al.. (2021). Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. The AAPS Journal. 24(1). 11–11. 8 indexed citations
10.
Hamadani, Mehdi, John Radford, Carmelo Carlo‐Stella, et al.. (2020). Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 137(19). 2634–2645. 122 indexed citations
11.
McNamara, Christopher, Silvia Montoto, Toby A. Eyre, et al.. (2020). The investigation and management of follicular lymphoma. British Journal of Haematology. 191(3). 363–381. 20 indexed citations
12.
13.
Jurczak, Wojciech, Simon Rule, William Townsend, et al.. (2017). First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes. Blood. 130. 2778–2778. 3 indexed citations
14.
Ardeshna, Kirit M., Kate Cwynarski, David C. Linch, et al.. (2017). Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience. Blood. 130. 3387–3387. 3 indexed citations
15.
Coulter, Eve, Andrea Pepper, Silvia Mele, et al.. (2017). In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia. Haematologica. 103(3). 497–505. 11 indexed citations
16.
Marcus, Robert, Andrew Davies, Kiyoshi Ando, et al.. (2017). Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England Journal of Medicine. 377(14). 1331–1344. 461 indexed citations breakdown →
17.
Townsend, William & David C. Linch. (2012). Hodgkin's lymphoma in adults. The Lancet. 380(9844). 836–847. 92 indexed citations
18.
19.
Pettit, Allison R., Christopher Quinn, Kelli P. A. MacDonald, et al.. (1997). Nuclear localization of RelB is associated with effective antigen-presenting cell function. The Journal of Immunology. 159(8). 3681–3691. 122 indexed citations
20.
Kaufman, Herbert E., et al.. (1970). The Chemotherapy of Herpes Iritis With Adenine Arabinoside and Cytarabine. Archives of Ophthalmology. 84(6). 783–787. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raymond E. Felgar Breakdown of academic impact, for papers by Marianne Tinguely Breakdown of academic impact, for papers by Françoise Rigal‐Huguet Breakdown of academic impact, for papers by Alessandro Gozzetti Breakdown of academic impact, for papers by E. Hessey Breakdown of academic impact, for papers by Monica Monti Breakdown of academic impact, for papers by Cyrille Touzeau Breakdown of academic impact, for papers by José C. Villasboas Breakdown of academic impact, for papers by Meyer R. Heyman Breakdown of academic impact, for papers by J P Sloane
Rankless by CCL
2026